Government Cracks Down on Fake DNA-Based Medicine
By Eric Hal Schwartz,
In The Capital
| 05. 13. 2014
Any medical advance always brings along con men hoping to exploit the news with useless or even dangerous "medicine" of their own that they can lie about to sell to people who don't yet know how to spot fakes. Personalized medicine, treatment that uses genetic information to improve people's health, has now reached the point where companies eager to cheat people excited by its promise are sprouting up. The Federal Trade Commission has taken the first steps to quashing these 21st century snake-oil salesmen in a settlement finalized Tuesday with two "personalized nutritional supplement" companies.
Genomics and personalized medicine has the potential to help countless people by diagnosing cancer earlier, treating genetic diseases and even restoring organs and tissue. It's still early days for the field and the FDA and FTC are watching closely as techniques and products are developed. GeneLink, Inc. and its former subsidiary, foruTMInternational Corp., were also watching, and created an entire scam around the idea of personalized medicine. Customers would send them a cheek swab and the companies claimed they would analyze the DNA and...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...